Gravity Analytica

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ARCT 12.16.2024

SERA-AI Powered Highlights

Drug:unknown KOSTAIVE®

Diseases:COVID-19

Date of Upcoming Event:2025-01-15

Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference

Full Press Release SEC Filings Our ARCT Tweets

About Gravity Analytica

Recent Filings

PDF Version

SAN DIEGO--(BUSINESS WIRE)--Dec. 16, 2024--Arcturus Therapeutics Holdings Inc.(the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced thatJoseph Payne, President & Chief Executive Officer, will present at the 43^rdAnnualJ.P. Morgan Healthcare ConferenceinSan Francisco, onWednesday, January 15, 2025, at9:45 a.m. Pacific Time.

A webcast and replay of the presentation will be available on the Investor Relations/Events section of the Company’s website at:https://ir.arcturusrx.com/investor-calendar.

About Arcturus

Founded in 2013 and based inSan Diego, California,Arcturus Therapeutics Holdings Inc.(Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture inJapan,ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in theU.S.,Europe,Japan,China, and other countries). For more information, visitwww.ArcturusRx.com. In addition, please connect with us onTwitterandLinkedIn.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241216064393/en/

Arcturus TherapeuticsPublic Relations & Investor RelationsNeda SafarzadehVP, Head of IR/PR/Marketing(858) 900-2682IR@ArcturusRx.com

Source:Arcturus Therapeutics Holdings Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com